After paying $305m, Anne Wojcicki is back at the helm of 23andMe – the genetic data company she cofounded, ran, then left ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

After a couple of months of non-stop litigation, counsel for the debtor at Paul, Weiss and for the acquirer—a newly formed ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

TTAM Research Institute acquires 23andMe in a $305 million bankruptcy sale, transitioning the DNA testing giant to a ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

MAIA Biotechnology enrolls first patient in expansion of phase 2 clinical trial for ateganosine in advanced non-small cell lung cancer: Chicago Friday, July 11, 2025, 12:00 Hrs [I ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki, rejecting California’s attempt to delay the deal over privacy concerns.